Mainz Biomed NV

Chart & Performance

D1W1MN

P/E

—

P/S

10.90

EPS

—

Div Yield, %

—

Shrs. gr., 5y

1.35%

Rev. gr., 5y

1.70%

Revenues

537k

-39.92%

Net income

-16m

L-25.13%

CFO

-11m

L-35.75%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.

URL

https://www.mainzbiomed.com/

IPO date

Nov 04, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT